糖尿病测试用品制造商Home Diagnostics Inc(HDIX)宣布，已同意接受日本医疗设备制造商尼普洛株式会社(Nipro Corp)的收购，交易价格为2.15亿美元。

　　根据协议，尼普洛将为每股Home Diagnostics股票支付11.50美元，较后者周二收盘价6.05美元溢价90%。

　　拟议中的这项交易已获得双方董事会的批准，而且拥有大约15%的Home Diagnostics股票的股东将预受要约，以支持此项出售。

　　尼普洛将于2月10日前后对Home Diagnostics的股票展开一次要约收购。

　　此项交易包括一项650万美元的解约金，如果Home Diagnostics接受来自另一家公司的收购要约的话。

　　此项交易尚需接受监管评估。
 
Japan's Nipro to buy Home Diagnostics for $215M
Diabetes testing supplies maker Home Diagnostics Inc. said Wednesday it has agreed to be acquired by Nipro Corp., a medical device maker from Japan, for $215 million.

The companies said Nipro has offered $11.50 a share for Home Diagnostics shares, a 90 percent premium over Tuesday's closing price of $6.05.

Home Diagnostics' shares climbed 89 percent to $11.45 in premarket trading.

The proposed sale has already been approved by the boards of both companies, and shareholders who own about 15 percent of Home Diagnostics shares will tender their stock in support of the sale.

Nipro will begin a tender offer for Home Diagnostics shares starting around Feb. 10, the companies said.

The deal includes a $6.5 million termination fee if Home Diagnostics accepts another buyout offer from a different company.